کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2112362 | 1084368 | 2016 | 11 صفحه PDF | دانلود رایگان |
• Targeting of the cancer stem cells is the goal of recent studies as they are responsible for tumor relapse and metastasis.
• CSC targeted DC based immunotherapy seems to be a potentially powerful choice for prevention or treatment of cancers.
• There are rare studies concerning the use of DCs for targeting of CSCs.
• The aim of our present study was to evaluate the effectiveness of a DC-based vaccine against CSCs in mouse melanoma model.
Cancer stem cells (CSCs) are demonstrated to be usually less sensitive to conventional methods of cancer therapies, resulting in tumor relapse. It is well-known that an ideal treatment would be able to selectively target and kill CSCs, so as to avoid the tumor reversion. The aim of our present study was to evaluate the effectiveness of a dendritic cell (DC) based vaccine against CSCs in a mouse model of malignant melanoma. C57BL/6 mouse bone marrow derived DCs pulsed with a murine melanoma cell line (B16F10) or CSC lysates were used as a vaccine. Immunization of mice with CSC lysate-pulsed DCs was able to induce a significant prophylactic effect by a higher increase in lifespan and obvious depression of tumor growth in tumor bearing mice. The mice vaccinated with DCs loaded with CSC-lysate were revealed to produce specific cytotoxic responses to CSCs. The proliferation assay and cytokine (IFN-γ and IL-4) secretion of mice vaccinated with CSC lysate-pulsed DCs also showed more favorable results, when compared to those receiving B16F10 lysate-pulsed DCs. These findings suggest a potential strategy to improve the efficacy of DC-based immunotherapy of cancers.
Journal: Cancer Letters - Volume 374, Issue 1, 28 April 2016, Pages 175–185